Dana-Farber researchers present findings at 2025 San Antonio Breast Cancer Symposium
8 Key Takeaways
-
1
Dana-Farber presented over 50 studies at SABCS 202
-
2
Focus on innovations like mobile health to support young breast cancer survivors.
-
3
Targeted therapies showed promise in previously treated metastatic cases.
-
4
Dr. Nolan Priedigkeit awarded 2025 Rising Star for his work.
-
5
Liquid biopsies may predict responses to HER2 treatments.
-
6
T-DM1 offered positive outcomes for older patients.
-
7
Palbociclib showed potential to delay CNS metastases.
-
8
Emphasis on evidence-based approaches in breast cancer management.
At the 48th annual San Antonio Breast Cancer Symposium, Dana-Farber Cancer Institute unveiled over 50 innovative studies, discussing progressive strategies in breast cancer treatment. Key highlights include research on improving quality of life in young women through smartphone tools, the efficacy of targeted therapies for metastatic cases, and the promise of liquid biopsies in predicting treatment responses. Notably, Drs. Nolan Priedigkeit and Sara Tolaney received prestigious awards for their contributions to breast cancer research, emphasizing the institute's commitment to advancing care in this field.
Listen Tab content
